Skip to content
Mesothelioma.net
phone iconCall1-800-692-8608 chat icon Chat 24/7 Live Chat
Menu
  • Malignant Mesothelioma
    • About Mesothelioma
      • How to Survive Mesothelioma
      • 100 Questions & Answers about Mesothelioma (Free Book)
      • Symptoms
      • Diagnosis
      • Prognosis
      • Life Expectancy
    • Types
      • Pleural
      • Peritoneal
      • Epithelioid
      • Sarcomatoid
      • Biphasic
    • Stages
      • Stage 1
      • Stage 2
      • Stage 3
      • Stage 4
    • Additional Information
      • Causes
      • Asbestos and Its Dangers
      • Facts
      • Support
      • Financial Compensation
      • FREE Mesothelioma Packet
  • Treatment
    • Treatment Options
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Multimodal Therapy
      • Medications
      • Palliative Treatment
    • Find Top Doctors
      • Doctors
      • Treatment Centers
      • Treatment & Doctors Near You
      • New Treatments
      • Care Providers
      • Clinical Trials
      • Costs
  • Asbestos Trusts
  • Compensation
  • Veteran Assistance
    • Mesothelioma and Veterans
      • VA Claims for Mesothelioma
      • Vietnam Veterans
    • Military Branches and Asbestos
      • Navy Veterans
      • Navy Ships
      • Marine Corps Veterans
      • Army Veterans
      • Air Force Veterans
      • U.S. Coast Guard
  • Surviving Mesothelioma
  • About Us / Contact
  • Home
  • ›
  • Malignant Mesothelioma
  • ›
  • Diagnosis
  • ›
  • Biomarkers and Blood Tests
Page Updated: June 22, 2022

Biomarkers and Blood Tests for Mesothelioma

Anne Courtney Page Medically Reviewed and Edited by Anne Courtney, AOCNP, DNP

FREE Mesothelioma Packet

Fact Checked

This page has been fact-checked by a Doctor of nursing practice specializing in Oncology and has experience working with mesothelioma patients.

FREE Mesothelioma Packet

Sources of information are listed at the bottom of the article. We make every attempt to keep our information accurate and up-to-date. 

Please Contact Us with any questions or comments.

Mesothelioma testing is rarely simple or straightforward, and many patients undergo multiple diagnostic tests to confirm or rule out cancer. While imaging and biopsies remain essential, biomarkers and blood tests for many cancer types are gaining interest, including mesothelioma.[1] Research continues to improve the technique of using biomarkers to aid in detecting the presence of cancer.

FREE Mesothelioma Packet

What Tests Are Done to Diagnose Mesothelioma?

Mesothelioma testing is complicated and varies depending on the patient. There is no single test that can diagnose this rare cancer. Doctors use a variety of tests to determine if a patient has mesothelioma:

  • Physical exam and symptom review
  • Imaging scans, including X-rays, CT, MRI, and PET scans
  • Biopsies to examine the cells under a microscope
  • Blood tests for characteristic biomarkers

What Are Biomarkers?

A biomarker is a molecule of biological origin found in tissues, blood, or other bodily fluids. They are characteristic of some process or disease.[2] Biomarkers are not necessarily bad. For example, certain hormones in urine are biomarkers indicating pregnancy. Biomarkers are also useful in diagnosing diseases, including cancer.

Pathologists can find various types of biomarkers in the blood to indicate cancer in the body. These include proteins, nucleic acids like DNA and RNA, antibodies, and others.

If there is a biomarker cancer cells are known to produce, its presence in the blood can be part of an overall diagnosis. Some biomarkers are general to all types of cancers. Others may indicate a specific type.[3]

Currently, there is no approved biomarker used for mesothelioma screening purposes. Doctors still use blood tests to look for biomarkers because they add to the diagnostic picture. No single biomarker always indicates mesothelioma, but certain patterns help distinguish between it and other types of cancer.

Is There a Blood Test for Asbestos Exposure?

There is no asbestos blood test. To find asbestos fibers in the body requires a biopsied tissue sample. Doctors don’t usually directly test for asbestos. Exposure usually occurred decades earlier. Instead, they look for a response to that exposure: symptoms, pleural plaques or thickening, tumors, inflammation, and scarring.

Mesothelioma Tests for Biomarkers

Doctors use a wide range of biomarkers when diagnosing mesothelioma. No biomarker is a perfect indicator, but together with other diagnostic tests, they help confirm the diagnosis.

Mesothelin

One of the most specific biomarkers for mesothelioma is soluble mesothelin-related protein (SMRP). These proteins are produced and released by cancer cells of the mesothelium.

SMRP is normal in mesothelium cells but often overproduced in cancerous cells. The MESOMARK assay is a blood test that measures SMRP levels.[4]

Studies indicate the MESOMARK assay can be a useful diagnostic tool for mesothelioma. Most patients with mesothelioma have elevated levels of SMRPs compared to healthy people.

Unfortunately, this test is not perfect. Some patients with mesothelioma do not have elevated levels. In addition to diagnosing cancer, MESOMARK can also be used to track the progress of mesothelioma. In patients with mesothelioma, levels of SMRP usually go up as the condition worsens.[5]

There is potential for SMRP as a biomarker to act as an early test for mesothelioma. People exposed to asbestos could be screened using the assay to detect rising levels of SMRP early, allowing earlier diagnosis and better treatment options.[6] More research is needed before it’s used for screening purposes.

Another test used to detect mesothelin proteins is the N-ERC/mesothelin test. This test is similar to the MESOMARK assay but can be more accurate thanks to a special enzyme to detect the proteins. It also can be used for other cancers, such as pancreatic and ovarian cancers. While this newer test is more accurate, it is still not a definitive biomarker test.[7]

Fibulin-3

Another biomarker for mesothelioma is the protein fibulin-3. Like SMRP, this protein is released in larger quantities in mesothelioma cancer cells. The protein can be found in blood and pleural fluid.

One early study using fibulin-3 as a biomarker found it was 95% effective at ruling out mesothelioma, and the test was more than 96% more effective at detecting it. Additional research is needed before it can be used for mesothelioma screening.[8]

Osteopontin

Osteopontin is another protein typically found at higher levels in the blood of patients with mesothelioma. There are, however, other types of cancer that also elevate blood levels of this bone-related protein. These include lung cancer, breast cancer, and colon cancer.

Tests for osteopontin may be most useful in screening people with known asbestos exposure. There is a strong connection between the levels of this biomarker and the extent of asbestos exposure. It may be useful in determining how much exposure a person received and, therefore, the level of risk for developing mesothelioma.[9]

Megakaryocyte Potentiating Factor (MPF)

Another potentially useful biomarker is megakaryocyte potentiating factor or MPF. MPF is a protein made by a precursor of mesothelin.

No one yet understands what MPF does in the body; however, it has been detected at elevated levels in people known to have mesothelioma. Other types of cancer may cause elevated levels of MPF, like ovarian and pancreatic cancer.

One study found levels of MPF changed before and after tumor removal surgery. The amount of MPF in the blood varied depending on how much of the tumor could be removed. This means it could be a useful test for determining how much cancerous tissue remains after surgery.[10]

Other Mesothelioma Biomarkers

There are a few other biomarkers that doctors sometimes use but that are less important and informative in diagnosing mesothelioma:[11][12]

  • 8-oxo-dGuo/8-OHdG. These biomarkers are signs of oxidative stress in DNA. They signal that DNA has been damaged by something, like asbestos, but are not specific to mesothelioma.
  • Epidermal Growth Factor Receptor. EGFR similarly lacks specificity, but it is also known to play role in how mesothelioma develops.
  • Estrogen Receptor-β. While this marker isn’t very useful for diagnosing mesothelioma, it can help develop a prognosis. It indicates how a patient might respond to standard chemotherapy.
  • Interleukin-6/VEGF. Mesothelioma cells excrete interleukin-6, a marker of inflammation and immune response. Interleukin-6, in turn, results in the production of vascular endothelial growth factor. Researchers are targeting these markers for treatments.
  • Calretinin. Calretinin is a protein that has been useful in identifying epithelial and biphasic, but not sarcomatoid mesothelioma.

The Latest in Mesothelioma Biomarker Research

No biomarker is yet a perfect diagnostic factor for mesothelioma. Researchers continue to investigate compounds to improve diagnoses with some potential biomarkers currently under investigation:

  • High Mobility Group Box 1 Protein. HMGB1 is a protein researchers believe may be diagnositic for mesothelioma. Mesothelioma cells release the protein as they die, triggering an inflammatory response. Studies indicate that a certain form of the HMGB1 could differentiate between healthy asbestos-exposed individuals and those with mesothelioma.[13]
  • Claudins. This group of proteins are produced in epithelial cells. Researchers have found that claudin-15 is specifically expressed in mesothelial cells. They found the protein in mesothelioma tissue but not in the tissue of other cancers. This protein may help distinguish between mesothelioma and other cancer types.[14]

Tracking Biomarkers in At-Risk Patients

Blood tests for biomarkers have the potential to detect mesothelioma in patients; however, there are limitations. Research continues as scientists seek more accurate tests to diagnose mesothelioma specifically. In the meantime, these biomarker blood tests can help monitor mesothelioma risk in people exposed to asbestos in select cases.

Blood tests for biomarkers will hopefully have a role in routine use in the future. They are still not accurate enough to be utilized for widespread early detection of cancer. The most important thing is to discuss risk factors with your medical care team, and they can help determine the most appropriate screening protocols.

Get Your FREE Mesothelioma Packet

Page Medically Reviewed and Edited by Anne Courtney, AOCNP, DNP

Anne Courtney

Anne Courtney has a Doctor of Nursing Practice degree and is an Advanced Oncology Certified Nurse Practitioner. She has years of oncology experience working with patients with malignant mesothelioma, as well as other types of cancer. Dr. Courtney currently works at University of Texas LIVESTRONG Cancer Institutes.

Connect with Doctor of Nursing Practice Anne Courtney
References
  1. American Cancer Society. (2018, November 16). Tests for Malignant Mesothelioma.
    Retrieved from: https://www.cancer.org/cancer/malignant-mesothelioma/detection-diagnosis-staging/how-diagnosed.html
  2. National Cancer Institute. (n.d.). NCI Dictionary of Cancer Terms. Biomarker.
    Retrieved from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker
  3. National Cancer Institute. (2019, May 6). Tumor Markers.
    Retrieved from: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet
  4. Waknine, Y. (2007, January 29). FDA Approvals: Protege RX, Duet, Mesomark. Medscape.
    Retrieved from: https://www.medscape.com/viewarticle/551451
  5. Beyer, H.L., Geschwindt, R.D., Glover, C.L., Hellstrom, I., Hellstrom, K.E., Miller, M.C., Verch, T., Allard, W.J., Pass, H.I., and Sardesai, N.Y. (2007, April). MESOMARK: A Potential Test for Malignant Pleural Mesothelioma. Clin. Chem. 53(4), 666-72.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/17289801
  6. Hollevoet, K., Reitsma, J.B., Creaney, J., Grigoriu, B.D., Robinson, B.W., Sherpereel, A., Cristaudo, A., Pass, H.I., Nackaerts, K., Rodriguez Portal, J.A., Schneider, J., Muley, T., Di Serio, F., Baas, P., Tomasetti, M., Rai, A.J., and van Meerbeeck, J.P. (2012, May). Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: And Individual Patient Data Meta-Analysis. J. Clin. Oncol. 30(13), 1541-49.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383122/
  7. Imashimizu, K. Shiomi, K., Maeda, M., Aoki, N., Igarashi, K., Suzuki, F., Koizumi, M., Suzuki, K., and Hino, O. (2011). Feasibility of Large-Scale Screening Using N-ERC/Mesothelin Levels in the Blood for the Early Diagnosis of Malignant Mesothelioma. Exp. Ther. Med. 2(3), 409-11.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440716/
  8. Pass, H.I., Levin, S.M., Harbut, M.R., Melamed, J., Chiriboga, L., Donington, J., Huflejt, M., Carbone, M., Chia, D., Goodglick, L., Goodman, G.E., and Thornquist, M.D. (2012, October 11). Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma. N. Engl. J. Med. 367, 1417-27.
    Retrieved from: https://www.nejm.org/doi/full/10.1056/NEJMoa1115050
  9. Creaney, J., Yeoman, D., Demelker, Y. Segal, A., Musk, A.W., Skates, S.J., and Robinson, B.W. (2008, August). Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma. J. Thorac. Oncol. 3(8), 851-7.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/18670302
  10. Onda, M., Nagata, S., Ho, M., Bera, T.K., Hassan, R., Alexander, R.H., and Pastan, I. (2006, July). Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma. Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-06-0472
    Retrieved from: https://clincancerres.aacrjournals.org/content/12/14/4225
  11. Mesaros, C., Worth, A.J., Snyder, N.W., Christofidou-Solomidou, M., Vachani, A., Albelda, S.M., and Blair, I.A. (2015, May). Bioanalytical Techniques for Detecting Biomarkers of Response to Human Asbestos Exposure. Bioanalysis. 7(9), 1157-73.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487641/
  12. Ahmadzada, T., Reid, G., Kao, S. (2018, April 10). Biomarkers in Malignant Pleural Mesothelioma: Current Status and Future Directions. J. Thorac. Dis. 10(Suppl9), S1003-S1007.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949443/
  13. Adachi, Y., Yoshio-Hoshino, N., Aoki, C., and Nishimoto, N. (2010, June). VEGF Targeting in Mesotheliomas Using an Interleukin-6 Signal Inhibitor Based on Adenovirus Gene Delivery. Anticancer Research. 30(6), 1947-52.
    Retrieved from: https://ar.iiarjournals.org/content/30/6/1947
  14. Watanabe, M., Higashi, T., Ozeki, K., Higashi, A.Y., Sugimoto, K., Mine, H., Takagi, H., Ozaki, Y., Muto, S., Okabe, N., Matsumura, Y., Hasegawa, T., Shio, Y., Suzuki, H., and Chiba, H. (2021, June 15). CLDN15 is a Novel Diagnositc Marker for Malignant Pleural Mesothelioma. Scientific Reports. 11(12554), https://doi.org/10.1038/s41598-021-91464-0.
    Retrieved from: https://www.nature.com/articles/s41598-021-91464-0
View All References

Site Navigation

Home
Malignant Mesothelioma
How to Survive Mesothelioma
100 Questions & Answers about Mesothelioma (Free Book)
Surviving Mesothelioma - Beating the Odds (Free Book)
FREE Mesothelioma Packet
Symptoms
Shortness of Breath
Cough
Night Sweats and Fever
Weight Loss
Pain
Difficulty Swallowing
Fatigue and Muscle Weakness
Gastrointestinal Complications
Diagnosis
Pathology
Staging
Stage 1
Stage 2
Stage 3
Stage 4
Metastasis and Progression
Brain Metastasis
Biopsy
miRview Test
Imaging
Fine Needle Aspiration Biopsy in Mesothelioma
Biomarkers and Blood Tests
Calretinin
Prognosis
Remission
Recurrence
Death Rate
Life Expectancy
Search for a Mesothelioma Cure
Types
Pleural
Peritoneal
Epithelioid
Sarcomatoid
Biphasic
Pericardial
Testicular
Cell Types
Rare Subtypes of Mesothelioma
Deciduoid
Desmoplastic
Heterologous
Lymphohistiocytoid
Well-Differentiated Papillary
Tubulopapillary
Small Cell
Benign
Adenomatoid
Cystic
Unresectable
Localized
Idiopathic
Omental
Causes
Risk Factors
Latest Research
Genetic Components
Incidence
Latency Period
Mesothelioma Tumor
Health Insurance Coverage
Related Conditions
Immunodeficiency Disorders
Cholangiocarcinoma
Atelectasis
Pleural Plaques
Pleural Thickening
Pleural Effusion
Peritoneal Effusion (Ascites)
Mesothelial Hyperplasia and Proliferation
Pleuritis and Pleurisy
COPD
Anemia
Breast Cancer
Prevention
Complications
Misdiagnosis
Mesothelioma Commercial
Talcum Baby Powder
Lawyer
Lawsuits
Class Action Lawsuits
Settlements
Simian Virus 40
Differences From Other Cancers
Lung Cancer
Women
Children and Young Adults
Unknown Asbestos Exposure
Mesothelioma Without Asbestos
Cause of Death
Facts 
History
Awareness
Government and Research
National Mesothelioma Virtual Bank
Support
What to Expect
Living with Mesothelioma
Help a Loved One
Wrong and Right Things to Say
Caregivers
Financial Tips
Faith
Nutrition and Lifestyle
Intimacy
Mesothelioma and Fertility in Men
Fertility in Women with Mesothelioma
Emotional Health
COVID-19
Assisted Living
Hospice Care
Dying from Mesothelioma
Mourning
Coping Guide for Children
End-of-Life Decisions
Mesothelioma Awareness Day
Compensation for Victims
Lawyer
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington D.C.
Washington
West Virginia
Wisconsin
Wyoming
Lawsuit
Settlements
Statute of Limitations
Treatment
Surgery
Side Effects
Pneumonectomy
Extrapleural Pneumonectomy
Lobectomy
Pleurectomy/Decortication
Post Op Care
Pleurectomy/Decortication vs. Extrapleural Pneumonectomy
Peritonectomy/Cytoreductive Surgery
Thoracotomy
Thoracoscopy
Pericardiectomy
Wedge Resection
Pleurodesis
Pericardiocentesis
Prosthetics
Paracentesis
Thoracentesis
Chemotherapy
Side Effects
Heated Intraperitoneal
Radiation Therapy
Side Effects
Intensity-Modulated
Brachytherapy
Proton Therapy
Image-Guided
External Beam
Three-Dimensional
Multimodal Therapy
New Treatments
SMART Protocol
Gene Therapy
Suicide Gene Therapy
Tumor-Based p53 Therapy
Cryotherapy for Mesothelioma
Tumor Treating Fields
MicroRNA
Palliative Treatment
Osteopathic
Doctors
Treatment Centers
Treatment & Doctors Near You
Mesothelioma Experts
Medications
Alimta (pemetrexed)
Adriamycin (doxorubicin)
Avastin (bevacizumab)
Cytoxan (cyclophosphamide)
Gemzar (gemcitabine)
Keytruda (Pembrolizumab)
Mitomycin
Navelbine (vinorelbine)
Opdivo (nivolumab) and Yervoy (ipilimumab)
Paraplatin (carboplatin)
Platinol (cisplatin)
Rheumatrex (methotrexate)
Sutent (sunitinib)
Taxol (paclitaxel)
Medical Marijuana
Care Providers
Clinical Trials
Anetumab Ravtansine
Atezolizumab
Chimeric Antigen Receptor (CAR) T-Cell
Durvalumab
Immunotoxin
Interferon Alfa-2b
Onconase (Ranpirnase)
VISTA Protein
Costs
Immunotherapy
Nanotechnology
Hyperbaric Oxygen Therapy
Home Medical Equipment
HMGB1 Secretion
Photodynamic Therapy
Targeted Therapies
Apoptosis
Stem Cells
Lung Transplantation
Body-Based Therapies
Alternative Therapies
Paul Kraus’s Method
Doctors and Treatment in Canada
Asbestos Trusts
Veterans
VA Claims for Mesothelioma
Vietnam Veterans
Military Branches and Asbestos
Navy Veterans
Navy Ships
Aircraft Carriers
Battleships
Destroyers
Asbestos on Navy Cruisers
Submarines
Amphibious Ships
Minesweepers
Auxiliary Ships
Marine Corps Veterans
Army Veterans
Air Force Veterans
U.S. Coast Guard
Asbestos
Occupational Exposure
Construction Workers
Shipyard Workers
Ship Repair
Steel Mill Workers
Industrial Workers
Boiler Workers
Power Plant Workers
Firefighters
Automotive Workers
Roofers
Oil Refineries
Mining
Transportation Industry
Machine Operators
Farmers and Agricultural Workers
Migrant Workers
Electrical Wiring
Labor Unions
Prisons
Chimneys, Furnaces, and Wood Stoves
Fiberglass Connection to Mesothelioma
Home Remodeling
School Buildings, Teachers
For Tech Students
Cancer
Lung Cancer
Pleural Based Cancers
Ovarian Cancer
Ovarian Cancer Lawsuits
Companies That Used Asbestos
Awareness and Education
Types of Asbestos & Mesothelioma Risk
Asbestosis
Interstitial Lung Disease
Smoking
Asbestos Ingestion
Exposure in a Natural Disaster
Ban Asbestos
Libby, Montana
Recycling Asbestos
Asbestos Detection
Legal Information by State
Canada
Mexico
United Kingdom
Australia
  • Malignant Mesothelioma
    • Treatment
    • Asbestos Trusts
  • Compensation
    • Veteran Assistance
    • Surviving Mesothelioma
  • FREE Mesothelioma Packet
    • Mesothelioma News
    • About Us / Contact
  • Privacy Policy
    • Disclaimer
    • Editorial Guidelines and Standards
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.
The information provided by Mesothelioma.net is not a substitute for professional medical advice, diagnosis or treatment.

Mesothelioma.net

5430 LBJ Freeway Suite 1200
Dallas, Texas 75240

Serving mesothelioma victims nationwide

1-800-692-8608

  • facebook
  • twitter
© 2022 Mesothelioma.net